The study found an increased risk of hypoglycemia with combination therapy, which decreased with prolonged use. Thiazolidinedione monotherapy was linked to higher mortality compared to GLP-1 RA ...

When a GLP-1 RA is prescribed along with insulin, it can increase the odds of hypoglycemia. Because GLP-1 RAs slow digestion, they may affect how some medications are absorbed. If you have ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

GLP-1 RA also significantly reduced the risk of ... (less than 0.1% for both), pancreatic cancer (0.2% for both), severe hypoglycemia (2.5% vs 2.3%), and retinopathy (3.2% for both) — did ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...

The GLP-1 RA and placebo groups had no differences in the risk for serious adverse events, including acute pancreatitis and severe hypoglycemia. "Taken together, these results and the breadth of ...

Study: Optimizing Nutrition, Diet, and Lifestyle Communication in GLP-1 Medication ... triggering hypoglycemia, helping reduce appetite and consequently body weight. However, GLP-1 RA therapy ...

The researchers found that the incidence of VTE was 11.0 versus 12.9 events per 1,000 patient-years in the GLP-1 RA and DPP-4 inhibitor cohorts, respectively, with an 18 percent lower risk for VTE ...

Ozempic (semaglutide) is a GLP-1 RA (glucagon-like peptide-1 receptor ... This includes things like heart disease, kidney disease, hypoglycemia, diabetic neuropathy (nerve damage), and problems ...

Twelve GLP-1 RA medications were studied, 3 that are FDA-approved (liraglutide, semaglutide, and tirzepatide) and 9 that are not yet approved for weight management. Treatment periods lasted from ...

The researchers found that the incidence of VTE was 11.0 versus 12.9 events per 1,000 patient-years in the GLP-1 RA and DPP-4 inhibitor cohorts, respectively, with an 18% lower risk for VTE for ...